Hcyb1 是一种高度选择性的，具有口服活性的 PDE2 抑制剂。Hcyb1 对 PDE2A 具有高度选择性抑制作用 (IC50=0.57 μM)，比作用于其他 PDE 家族成员的选择性高 250 多倍。Hcyb1 具有神经保护和抗抑郁作用。
货号:ajcx36796
CAS:N/A
分子式:C24H20N4O
分子量：380.44
溶解度:DMSO : 62.5 mg/mL (164.28 mM; Need ultrasonic)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Hcyb1 is a highly selective, orally active PDE2 inhibitor. Hcyb1 has a highly selective inhibition of PDE2A (IC50=0.57 μM) and over 250-fold selectivity against other recombinant PDE family members. Hcyb1 produces neuroprotective and antidepressant‐like effects most likely mediated by cAMP/cGMP-CREB-BDNF signaling[1].

Hcyb1 (1~100 nM; 10 minutes) increases cGMP levels by 1.7~2.3 folds[1].Hcyb1 (1 nM; 24 hours) increases both cGMP and cAMP levels[1].Hcyb1 (24 hours) treatment also increases the levels of phosphorylation of CREB and BDNF in HT-22 cells[1].Hcyb1 promotes HT-22 cell viability and increase the cGMP and cAMP accumulation in HT-22 cells[1].Hcyb1 exhibits the concentration- and time-dependent effects on cell viability in HT-22 cells[2].

Hcyb1 (0.5, 1, and 2 mg/kg, i.g.) decreases the immobility time in both forced swimming and tail suspension tests, without altering locomotor activity[3].

[1]. Li Liu, et al. The neuroprotective and antidepressant-like effects of Hcyb1, a novel selective PDE2 inhibitor. CNS Neurosci Ther. 2018 Jul;24(7):652-660.
[2]. Meng-Jia Zhu, et al. Phosphodiesterase 2 inhibitor Hcyb1 reverses corticosterone-induced neurotoxicity and depression-like behavior. Psychopharmacology (Berl). 2020 Nov;237(11):3215-3224.